Loss of and high COX2 () expression in metastatic colorectal cancer.

Lack of expression of the tumour suppressor gene caudal-type homeobox 2 () associates with poor outcomes in early stage colorectal cancer (CRC). Yet its prognostic value in the context of other prognostic biomarkers in metastatic CRC (mCRC) is unknown. Overexpressed cyclooxygenase-2 (COX2) has been reported in advanced CRC. However, CDX2 and COX2 relationship in mCRC remains undetermined. We aimed to assess their expression in mCRC tumours from a clinically characterised cohort and their influence on overall survival (OS) and progression-free survival (PFS) in first line. Among 720 consecutive mCRC patients, 346 had tumour samples appropriate for tissue microarray assembly and immunohistochemistry analyses. Clinical and survival data were retrospectively assessed. Loss of expression was detected in 27 (7.8%) samples, enriched in poorly differentiated tumours (20%; < 0.01) and in those with the p.V600E variant (40%; < 0.01). Most tumours (93.4%) expressed COX2. COX2-negative samples were enriched in poorly differentiated mCRC. In unadjusted analyses, median OS ( < 0.001) and median PFS ( < 0.05) were inferior for patients with CDX2-negative versus CDX2-positive tumours. In conclusion, loss of was significantly associated with poorly differentiated mCRC and p. allele and a prognostic marker of worse OS.